QLC5508 combined with other cancer drugs for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase Ib/II, open-label, multi-center study in China uses a dose-escalation followed by dose-expansion design to study QLC5508 in combination with other anti-cancer agents. The dose-escalation phase enrolls patients who have progressed on or are intolerant to standard therapies to identify safe and tolerable dose levels, and the dose-expansion phase enrolls patients who have not received prior treatment for advanced/metastatic disease. Key outcomes include safety, tolerability, pharmacokinetics, and anti-tumor activity measured by RECIST v1.1. Combinations being tested include QL1706, QL2107, paclitaxel, and platinum chemotherapy (cisplatin or carboplatin).

Why it matters

Who can join: the full rules

Inclusion Criteria:

* At least 18 years of age at screening;
* Histologically or cytologically confirmed advanced solid tumors:

Dose escalation part will enroll participants who have progressed on or are intolerant to available standard therapies.

Dose expansion part will enroll participants who have not received prior treatment for advanced/metastatic diseases.

* At least one measurable target lesion according to RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0\~1
* Life expectancy ≥12 weeks
* Female or male participants should be willing to use appropriate contraceptive measures throughout the study;
* Female participants should have a negative blood pregnancy test within 7 days prior to the first dose or have evidence of non-childbearing potential;
* A signed written Informed Consent Form

Exclusion Criteria:

* . Received or undergoing any of the following treatment:

  1. Previous or current treatment with B7-H3 targeted therapy
  2. Previous or current treatment with topoisomerase I inhibitors
  3. Previous treatment with cytotoxic chemotherapy, investigational agents, traditional Chinese medicine with an anti-tumor indication and antitumor drugs within 14 days prior to the first dose
  4. Previous treatment with macromolecular antitumor drugs within 28 days prior to the first dose

  f. Radiotherapy with a limited field of radiation within 2 weeks prior to the first dose; or more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks prior to the first dose e. Pleural effusion or ascites requiring clinical intervention; or presence of pericardial effusion f. Major surgery within 4 weeks prior to the first dose g. Brain metastases; leptomeningeal or brainstem metastases; or spinal cord compression
* Unresolved AEs ≥ Grade 2 (CTCAE v5.0) from prior therapy except for alopecia and residual neuropathy
* Previous or concurrent primary malignancies
* Inadequate bone marrow reserve or organ dysfunction
* Evidence of cardiovascular risk
* Evidence of current severe or uncontrolled systemic diseases
* Severe infection within 4 weeks prior to the first dose; or uncontrolled active infection at screening
* Known or suspected interstitial lung disease; or other moderate to severe pulmonary diseases that significantly impair respiratory function and may interfere with the detection or management of drug-related pulmonary toxicity
* High risk of gastrointestinal or abdominal bleeding 10. Gastrointestinal diseases of clinical significance within 3 months prior to the first dose
* History of severe neuropathy or mental disorders
* History of severe hypersensitivity reaction, severe infusion reaction or idiosyncrasy to drugs chemically related to QLC5508 or any of the components of QLC5508
* Unlikely to comply with study procedures and requirements in the opinion of the investigator
* Any disease or condition that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments

Where it's running

• Shanghai East Hospital
  Shanghai, China Recruiting

Study contacts

• Study coordinator: Qianyun Liu, Master
• Email: qianyun.liu@qilu-pharma.com
• Phone: +8653155821177

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• SGT003 in people with advanced solid tumors

  This early-phase study tests SGT003 in adults with advanced solid tumors to see if it is safe and tolerable and to get a first look at how it behaves in the body and any early signs of benefit.

  Recruiting Phase 1/2 Beijing Sungen Biomedical Technology Co., Ltd · Beijing, Beijing Municipality · NCT07811037

• YSCH-01 Nebulized Therapy for Lung Metastases in NSCLC and Advanced Solid Tumors

  A first-in-human, early-phase study tests a nebulized therapy called YSCH-01 to see if it is safe and shows any signs of benefit for adults with NSCLC or other cancers that have spread to the lungs.

  Recruiting Early Phase 1 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing · NCT07793500

• Personalized neoantigen-pulsed dendritic cell injections for malignant solid tumors

  This study tests personalized dendritic cell injections, with or without immune checkpoint inhibitors, to see if they are safe and can help patients with advanced solid tumors.

  Recruiting ZSky Biotech Inc · Qinhuangdao, Hebei · NCT07752953

• STX-003 in advanced solid tumors given by IV, alone or with pembrolizumab

  This study tests STX-003, given by IV, to see if it is safe and potentially effective for patients with advanced solid tumors, either alone or with pembrolizumab.

  Recruiting at 4 sites Phase 1/2 Strand Therapeutics Inc. · Scottsdale, Arizona and 3 other locations · NCT07751042

• ARV-6723 alone or with pembrolizumab in adults with advanced solid tumors

  This study tests ARV-6723, by itself or with pembrolizumab, to see if it is safe and could help the immune system fight advanced solid tumors in adults.

  Recruiting at 4 sites Phase 1/2 Arvinas Inc. · New York, New York and 3 other locations · NCT07749586

• BG-85738 alone or with other anticancer drugs in RAS-mutant advanced or metastatic solid tumors

  This study tests BG-85738, alone or with other cancer drugs, in adults whose solid tumors have RAS mutations and have progressed.

  Recruiting at 3 sites Phase 1 BeOne Medicines · South Brisbane, Queensland and 2 other locations · NCT07746141

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.